Summary & Overview
HCPCS Level II J8612: Methotrexate (xatmep), Oral, 2.5 mg
HCPCS Level II code J8612 denotes oral methotrexate (xatmep), 2.5 mg, a commonly used systemic antimetabolite for oncologic and certain autoimmune indications. Nationally, accurate coding for oral chemotherapeutic agents matters for pharmacy billing, benefit design, prior authorization workflows, and patient cost-sharing. Standardized HCPCS reporting supports consistent claims adjudication across payers and informs coverage policy discussions.
Key payers included in the overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synopsis of what J8612 represents, how it is typically billed and where it is dispensed, and the payer landscape relevant to reimbursement and coverage. The publication outlines common billing considerations, typical site-of-service expectations (outpatient pharmacy or clinic dispensing), and notes on clinical context for use.
This summary frames benchmarks and policy-relevant details at a national level: expected places of service, common modifiers encountered in claims (listed separately), and where to find related coding guidance. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code J8612 represents Methotrexate (xatmep), oral, 2.5 mg. This code is used for billing oral methotrexate tablets supplied for systemic therapy.
-
Service type: Oral systemic medication
-
Typical site of service: Outpatient pharmacy or clinic dispensing for ambulatory patients
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J8612 is an adult or pediatric patient with an inflammatory or oncologic indication requiring low-dose oral methotrexate therapy (xatmep), supplied as 2.5 mg tablets for weekly dosing. Common clinical scenarios include rheumatoid arthritis, psoriatic arthritis, severe plaque psoriasis, juvenile idiopathic arthritis, and certain chemotherapy adjunct or maintenance regimens for trophoblastic disease or leukemia.
In a routine outpatient workflow, a specialist (rheumatologist, dermatologist, pediatric rheumatologist, or hematology/oncology) prescribes oral methotrexate after evaluating baseline labs (CBC, liver function tests, renal function) and counseling on dosing frequency, teratogenic risk, and folic acid supplementation. The prescription is transmitted to a specialty pharmacy or clinic infusion/medication dispensing area where J8612 is billed as the HCPCS Level II drug code for the product. Periodic monitoring visits occur for efficacy and toxicity assessment, with lab monitoring typically every 4–12 weeks depending on stability. Dose adjustments, hold for intercurrent illness, or discontinuation are documented in the medical record and reflected in subsequent authorization and billing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |